Age-related macular degeneration (AMD) is a leading cause of vision loss in older adults. Current treatments mainly address advanced AMD, while early or intermediate stages rely only on micronutrient supplements. This highlights a critical gap in understanding the molecular drivers of early dry AMD and the need for strategies to prevent progression to geographic atrophy or choroidal neovascularization and vision loss.